Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Treatment of Opioid Use Disorder: Waiver Qualifying - Traverse City, MI - Monday, April 27, 2020

    Product not yet rated Contains 3 Component(s), Includes Credits

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices.

    image

    Host: Michigan Opioid Collaborative

    Monday, April 27, 2020 | 8:00 am - 5:00 pm

    The Hagerty Center
    Rm A+B
    715 E. Front St.
    Traverse City, MI 49686

    Overview

    Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

    Getting Started

    Please log in to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

    Learning Objectives 

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: December 2019

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAPA Credit Designation Statement

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee


    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAMNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received? Stock 
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVS None
    Tricia E. Wright, MD, MS, FACOG, DFASAM None


    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD (Chair)None
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRONone
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Sandy MetcalfeNone


    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartNone

    Target Audience

    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Claim CME

    1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
      Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
    4. Choose the type of credit (Physician or Non-physician) and click submit.
    5. Click the button “View/Print Certificate” to save or print your certificate
      Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior, Inc.

  • Part II: 16-Hour Waiver Training - AANP

    Contains 30 Component(s)

    This product contains 16 hours of education required for NP/PA/CRNA/CNM/CNS to qualify for a waiver to prescribe buprenorphine.

    Welcome Part II: 16-Hour Waiver Training, part of the 24-Hour Waiver Training. This course provides 16 hours of education needed for NPs, PAs, CRNAs, CNMs, and CNSs to receive a waiver to prescribe buprenorphine in an office-based setting. More information on waiver requirements can be found on the SAMHSA website. The curriculum covers: medical withdrawal management and maintenance; appropriate clinical use of FDA-approved medications for OUD treatment; initial and period patient assessment; addressing overdose, co-occurring disorders, and pain management; and counseling and recovery support services.

    To begin the online course, please ensure you are logged in (locate your name in the left-hand menu), then open the "Contents" tab, then locate the box that starts with  "1.1" in the first section. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

    After completing the online modules, corresponding quizzes, and applicable evaluations, you can claim credit for the course in the AANP CE Center. If you have any questions, please contact education@ASAM.org.

    Upon successful completion of Part I (8 hours) and Part II (16 hours), return to the AANP CE Center to submit your participation code (revealed at the end of Part II), fill out an evaluation, and claim credit.

    For 24-Hour Treatment of Opioid Use Disorder Course issuing AANP CE Credit: Click Here


    ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

    To qualify for a waiver, NPs and PAs must: 

    • Be licensed under state law to prescribe Schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD 

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat Opioid Use Disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver.

    This training is divided into two parts of 8 hours and 16 hours. If you have already completed the 8-hour DATA2000 course, you will only need to complete the second part of the 16-hour course.

    Available Now for CNS, CRNA, and CNM!

    H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, added qualifying clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives to list of practitioners eligible to prescribe buprenorphine until October 1, 2023. The ASAM Treatment of Opioid Use Disorder Course is available for qualifying clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives. 

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

  • 24-Hour Waiver Training: AANP

    Contains 2 Product(s)

    Free 24-hour CME education for nurse practitioners seeking to qualify for a waiver to prescribe buprenorphine in an office-based treatment setting.

    imageThis package contains 24 hours of required education for NP/PA/CRNA/CNM/CNS to qualify for a waiver to prescribe buprenorphine in an office-based setting. This curriculum covers all medications and treatments for opioid use disorder, in addition to other topics including medical maintenance and withdrawal, FDA-approved medications, initial and periodic patient assessment, and counseling and recovery support.

    The collaborative of ASAM, AAPA and AANP identified and reviewed this content to provide the NP/PA training required by CARA.

    The NP/PA 24-Hour Waiver Training is available for free in part by an unrestricted educational grant from Indivior.

    The 16-hour product developed includes all additional education required by the Comprehensive Addiction and Recovery Act (CARA) for physician assistants to successfully apply for a waiver to prescribe buprenorphine for office-based treatment of opioid use disorders.

  • The ASAM Fundamentals of Addiction Medicine 40-Hour CME Program (Online)

    Contains 65 Product(s)

    ​The ASAM Fundamentals of Addiction Medicine 40-Hour Program is an innovative educational program empowering primary care and other providers to identify, treat, and/or refer patients at risk for or with addiction. The curriculum is designed for healthcare professionals who received little addiction education during their medical training.​

    Program Overview


    The ASAM Fundamentals of Addiction Medicine 40-Hour Program is an innovative, fully online educational program empowering primary care and other providers to identify, treat, and/or refer patients at risk for or with addiction. Participants will learn how to recognize, screen, treat and refer patients with substance use disorders through 40 CME hours of interactive, case-based learning. This program is designed for healthcare professionals who received little addiction education during their medical training including physicians, clinicians, and other healthcare providers in primary care, emergency/urgent care, treatment centers and general psychiatry settings.

    Requirements and Format

    Registration to the program includes the online version of all activities. Participants may elect to complete activities in a live, in-person format when available to fulfill program requirements. Additional fees may apply for live-in-person events. Participants will have the opportunity to submit CME certificates for any of the required activities they have previously completed and will NOT need to re-take the activity. 

    Program Activities

    The ASAM Fundamentals of Addiction Medicine 40-Hour CME Program is comprised of five activities. All activities align with the nine identified addiction medicine competencies for primary care providers. ASAM has also gathered a collection of resources and tools reviewed by experts related to various topics of addiction medicine and working with patients at risk for or with substance use disorders (SUD) to supplement participant’s learning.  

    Click on the buttons below to be taken to each of the program activities. While it is recommended, you take the activities in the order below, participants may complete in any order they choose.

    Activity 1: FOAM   Activity 2: TOUD   Activity 3: ECHO Series   Activity 4: Pain Management   Activity 5: ElectiveS

    Activity Description

    • Activity 1 - The ASAM Fundamentals of Addiction Medicine Online (8 CME)
    • Activity 2 - The ASAM Treatment of Opioid Use Disorder Course (8 CME)
    • Activity 3 - Fundamentals of Addiction Medicine ECHO (FAME) Video-Conferencing Series (8 CME)
    • Activity 4 - Pain Management and Opioids (2.5 CME)
    • Activity 5 - Elective Topics (13.5 CME)

    If you experience any difficulties, please call the ASAM office at 301-656-3920 or email education@asam.org.

    Note: This program is for providers who are seeking additional knowledge about addiction medicine. This is not a certification or designed to prepare providers for certification exams. Providers interested in becoming an ABMS certified Addiction Specialist should go to http://www.theabpm.org and/or learn about Addiction Fellowship programs at https://www.acaam.org/accreditedfellowships/.  


    About the Program


    Program Overview

    The ASAM Fundamentals of Addiction Medicine 40-Hour Program is an innovative educational program empowering primary care and other providers to identify, treat, and/or refer patients at risk for or with addiction. Participants will learn how to recognize, screen, treat and refer patients with substance use disorders through 40 CME hours of interactive, case-based learning. This program is designed for healthcare professionals who received little addiction education during their medical training including physicians, clinicians, and other healthcare providers in primary care, emergency/urgent care, treatment centers and general psychiatry settings.

    Why Participate

    • Help patients that are already in your practice and be a part of the solution to the one of the nation’s deadliest epidemics 
    • Increase knowledge, skills and confidence for providers who may have received little or no addiction education during their medical training 
    • Learn how to integrate addiction medicine and payment models into your existing practice 
    • Connect with a community of colleagues and mentors for additional support with complex patients 
    • Experience content created specifically for primary care and other providers based on extensive needs-assessment 
    • Learn core competencies and knowledge needed to identify, treat, and refer patients with addiction to specialists when needed 
    • Earn a certificate of completion from ASAM upon completion of the 40-Hour CME Program

    Curriculum Topics

    • Attitudes towards addiction and treating patients with addiction 
    • Substance use disorders medications 
    • Neurobiology of addiction 
    • Screening, brief intervention, and referral to treatment (SBIRT) 
    • Motivational interviewing 
    • Medical and Psychiatric Co-morbidities 
    • Diagnosing substance use disorders 
    • Developing a treatment plan (including ASAM Criteria) 
    • Special populations (such as adolescents, pregnant women, etc) 
    • Referral to specialists

    Program Competencies


    Competencies and Curriculum Learning Objectives

    The ASAM Fundamentals of Addiction Medicine 40-Hour Program seeks to help learners achieve nine identified competencies in the addiction medicine field.

    The 40 hour CME curriculum is structured around nine competencies, of which each competency has several learning objectives. Activities in the curriculum will align with at least one of the learning objectives.

    1. Interact with patients and professional colleagues so as to display professionalism in all activities, by demonstrating commitment to the health and well-being of individuals and society through ethical practice, profession-led regulation, and high personal standards of behavior.
    2. Identify their feelings and attitudes that promote or prevent therapeutic responses to their patients with substance use disorders.
    3. Understand the addictive disorders as developmental biopsychosocial disorders.
    4. Take an evidence-based approach to detecting substance use disorders. 
    5. Respond to positive substance use screening results with brief counseling strategies, appropriate to the patient’s readiness to change.
    6. Use motivational interviewing with patients ambivalent about changing their substance use behavior.
    7. Conduct a biopsychosocial and developmental ambulatory assessment of an adult with a suspected SUD to match the patient to an appropriate level of care.
    8. List the indications, contraindications and duration of treatment of evidence based pharmacotherapy for alcohol, tobacco, and opioid use disorders and refer patient to specialty care where appropriate. 
    9. Reflect on the role of behavioral interventions for patients and families including formal intensive ambulatory and inpatient treatment and informal programs such as mutual aid groups in the recovery process for patients in their practice/ communities. 

    Financial Disclosures


    Commercial Interest Definition

    A commercial interest is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

    Disclosure of Commercial Support

    The American Society of Addiction gratefully acknowledges the support of the following companies in the development of The ASAM Fundamentals of Addiction Medicine Program. Indivior provided an unrestricted educational grant to assist with the development, implementation and evaluation of this Fundamentals Program.


    ASAM Fundamentals of Addiction Medicine Workshop Planning Committee

    Full Name Disclosure
    Miriam S. Komaromy, MD, FACP, FASAM (Chair) No Financial Relationships or Conflicts of Interest
    Angela L. Colistra, PhD, LPC, CAADC, CCS No Financial Relationships or Conflicts of Interest
    Zwaantje H. Hamming, FNP-C, CARN-AP No Financial Relationships or Conflicts of Interest
    Jill Mattingly, DHSc, MMSc, PA-C No Financial Relationships or Conflicts of Interest
    Kirk D. Moberg, MD, PhD, FASAM, FACP, FAAPL, CPE, MRO No Financial Relationships or Conflicts of Interest
    Lipi Roy, MD, MPH, DABAM Poynter Institute: Teacher/Trainer, Honorarium Florida
    Hospital: Teacher/Trainer, Honorarium
    Rescue Agency: Consultant/Advisory Board, Fee
    Kenneth A. Saffier, MD, FASAM No Financial Relationships or Conflicts of Interest
    Mario F. San Bartolomé, MD, MBA, MRO, QME, FASAM No Financial Relationships or Conflicts of Interest
    J. Paul Seale, MD, FASAM No Financial Relationships or Conflicts of Interest
    Peter L. Selby MBBS, CCFP, FCFP, MHSc, DFASAM, (Immediate Past Chair) J and J (Clinical Condition: Smoking cessation): Consultant/Advisory Board
    Other Research Support: receipt of drugs, supplies, equipment or other in-kind support

    Pfizer (Clinical Condition: smoking cessation): Consultant/Advisory Board
    Other Research Support: receipt of drugs, supplies, equipment or other in-kind support
    Research Grant: principal investigator, collaborator or consultant and pending grants as well as grants already received
    Speaker/Honoraria: speakers bureau, symposia, and expert witness

    ASAM CME Committee

    Full Name Disclosure
    Catherine Friedman, MD (Chair) No Financial Relationships or Conflicts of Interest
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM No Financial Relationships or Conflicts of Interest
    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO No Financial Relationships or Conflicts of Interest
    Zwaantje H. Hamming, FNP-C, CARN-AP No Financial Relationships or Conflicts of Interest
    Noel Ilogu, MD, MRCP, DFASAM No Financial Relationships or Conflicts of Interest
    Herbert L. Malinoff, MD, FACP, DFASAM No Financial Relationships or Conflicts of Interest
    Edwin A. Salsitz, MD, DFASAM No Financial Relationships or Conflicts of Interest

    Accreditation


    Accreditation Council for Continuing Medical Education (ACCME)

    image

    The American Society of Addiction Medicine has been awarded the highest level of Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) as a provider of continuing medical education (CME) for physicians. Accreditation in the ACCME System seeks to assure the medical community and the public that ASAM delivers education that is relevant to clinicians’ needs, evidence-based, evaluated for its effectiveness, and independent of commercial influence. 

    The ACCME System employs a rigorous process for evaluating institutions' CME programs according to standards that reflect the values of the educator community and aim to accelerate learning, inspire change, and champion improvement in healthcare. Through participation in accredited CME, clinicians and teams drive improvement in their practice and optimize the care, health, and wellness of their patients.

    Please see individual sessions for accreditation information for specific offerings.

    image


    Why Participate?


    Participants are saying....

    • “This is probably the best post-graduate training I've ever done…The webinar format was engaging and educational. I greatly appreciate the opportunity to have involved at that level.” – MD, Massachusetts
    • “Appreciate your effort to organize the training. It was a great experience. I'd definitely recommend this to my primary care colleagues.” – MD, Maryland
    • “…living in the Northeast, I’m afraid I get very provincial so it’s been really interesting to hear everybody…but it’s the across the country responses that have been so helpful.” – MD, Massachusetts
    • “Living in Alaska, the resources for substance abuse treatment is probably not as diversified as in other areas…so this clinic has been valuable to me… providing the information and talking, collaborating with other professions in the field to help provide the best care of the patients.” – NP, Alaska


    Extensive Development from Experts.... 

     

    The ASAM Fundamentals 40-Hour Program was developed over multiple years, beginning in 2013. ASAM’s committee of experts created, evaluated, and revised the Fundamentals program continuously to ensure providers received the highest quality, most up-to-date  education.


    Competency-Based Program Activities...


    The ASAM Fundamentals of Addiction Medicine 40-Hour Program is comprised of five components. All components and activities align with the nine identified addiction medicine competencies for primary care providers. ASAM has also gathered a collection of resources and tools reviewed by experts related to various topics of addiction medicine and working with patients at risk for or with substance use disorders (SUD) to supplement participant’s learning.   


    Positive Outcomes for Participants' Practice...

    Some of the most commonly reported changes as a result of the ASAM Fundamentals 40-Hour Program were:

    • Change in patient treatment plans
    • Change in approach to patients with SUDs
    • More frequent screening, e.g. screening all patients at least annually.
    • More use of screening tools or use of different screening tools.
    • More or better use of SBIRT
    • More or better use of MI techniques
    • Increased confidence in treating patients with addiction
  • Extended-Release Medication Formulations to Treat Opioid Use Disorder (OUD)

    Contains 3 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning information about all FDA-approved extended-release medications to treat OUD.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning information about extended-release medications to treat OUD. ASAM’s current Treatment of Opioid Use Disorder Course addresses extended-release formulations but does not review all available medications in-depth. This webinar will address knowledge gaps around pharmacology and will provide clinicians with information on all extended-release medications to treat OUD that are FDA-approved, or which have had an NDA submitted and approved by the FDA.

    Click on "Contents" to access the webinar.

    John Steinberg

    MD

    Dr. Steinberg is Board Certified in addiction medicine by the American Board of Addiction Medicine. He is a Fellow of the American Society of Addiction Medicine and served as president of the Maryland Society of Addiction Medicine from 1990 through 2005. He held a faculty position at the rank of Clinical Assistant Professor in the Departments of Family Medicine (1993-2007) and Psychiatry (1986-2007) at the University of Maryland School of Medicine teaching in addiction medicine and other topics and upon occasion continues to provide lectures on an ad hoc basis. He served as the head of the Division of Addiction Medicine in the Department of Internal Medicine at Greater Baltimore Medical Center from 1986 through 2001. He currently maintains a practice in internal medicine and addiction medicine and is an owner/partner in The Bergand Group, a state certified drug and alcohol outpatient treatment program. He uses medication for addiction treatment in his practice, including various formulations of injectable, extended release forms of both naltrexone and buprenorphine.

    CME Information and Disclosure Listing

    Date of Release: November 2019

    Approved Through: December 2020

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    Activity Planners

    NameNature of Relevant Financial Relationship
    Miriam Komaromy, MD, FACP, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    John Steinberg, MD, FASAMNone


    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD (Chair)None
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRONone
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAM*None
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Sandy MetcalfeNone

    *Activity Reviewer


    ASAM Medical Education Council


    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartNone

    This activity has been made available in part by an unrestricted educational grant from Indivior Inc.

  • Part 1: The ASAM Treatment of Opioid Use Disorder Course 8-Hour Online

    Product not yet rated Contains 8 Component(s), Includes Credits

    This course covers all approved medications to treat opioid use disorder and provides the 8 hours of education needed to receive a waiver to prescribe buprenorphine in an office-based setting.

    image

    Welcome to The ASAM Treatment of Opioid Use Disorder Course. This course provides 8 hours of education needed to receive a waiver to prescribe buprenorphine in an office-based setting. More information on waiver requirements can be found on the SAMHSA website. This course was updated in August 2018.

    To begin the online course, please log-in to your left and locate the box that says, "Module 1" in the "Contents" tab. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

    Instructions for completing the course can be found in the "Course Instructions" tab. After completing the online modules, corresponding quizzes, and applicable evaluations, return here to claim CME for the course. 

    If you have any questions, please contact education@ASAM.org.

    Daniel P. Alford

    MD, MPH, FACP, DFASAM

    Dr. Daniel P. Alford is an Associate Professor of Medicine, Assistant Dean of CME and Director of the Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program at Boston University School of Medicine. He is a diplomate in Addiction Medicine by the American Board of Addiction Medicine (ABAM).

    He is director of the Clinical Addiction Research and Education Unit medical director of the Office-Based Opioid Treatment (OBOT) program and of the Massachusetts Screening, Brief Intervention, Referral to Treatment Training and Technical Assistance (MASBIRT TTA) program and former program director for the Addiction Medicine Fellowship program at Boston Medical Center (BMC). Since 2001 he has served as the course director of the Chief Resident Immersion Training (CRIT) Program in Addiction Medicine: Improving Clinical and Teaching Skills for Generalists funded by NIDA. He is president of the Association for Medical Education and Research in Substance Abuse (AMERSA). In 2011, he was recognized as a Champion of Change by the White House. In 2014 he received the Health Education Award from the American Medical Association.

    R. Corey Waller

    MD, MS, DFASAM

    R. Corey Waller, MD, MS, FACEP, DFASAM, is an addiction, pain and emergency medicine specialist. Dr. Waller earned his bachelor's degree in biology and his master's degree in neuromolecular biology at Southwest Texas State University in San Marcos, Texas. He earned his medical degree at University of Texas Medical School in San Antonio. Dr. Waller completed his emergency medicine residency at Thomas Jefferson University in Philadelphia. He is board certified and fellowship trained in addiction medicine.

    Debra Newman

    PA-C, MPAS, MPH

    Debra R. Newman, PA-C, MPAS, MPH currently serves as treatment provider for First Judicial District Court, Adult Drug Court for Santa Fe and Rio Arriba Counties, New Mexico. Debra has worked in residential treatment as well as out-patient adult psychiatry and addiction medicine. Her passion for addiction medicine began with her association with Project ECHO in 2008. While employed at an FQHC in northern NM in a region historically plagued with the highest per capita heroin death rate in the nation, Debra worked under an addiction medicine psychiatrist and several family practice physicians waivered to prescribe buprenorphine. For over four years, she managed over 200 buprenorphine patients monthly, as the only full-time provider for these patients, while also carrying a caseload of HCV and chronic pain patients. She is currently working with the PA Foundation and NIDA on a grant examining the role of PA’s in drug courts.

    Marian Currens

    Associate Director, University of Maryland Medical Center Midtown Campus

    Marian Currens, CRNP is located in Baltimore, MD.

    Learning Objectives:

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorder
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorder
    6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorder
    8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone
    9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorder
    10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorder
    11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder
    12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    For 24-Hour Treatment of Opioid Use Disorder Course issuing AANP CE Credit: Click Here


    This training is divided into two parts of 8 hours and 16 hours. If you have already completed the 8-hour DATA2000 course, you will only need to complete the second part of the 16-hour course.

    Legislation
    Comprehensive Addiction and Recovery Act (CARA)
    ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

    HR6 - SUPPORT for Patients and Communities Act
    HR6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, added qualifying clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives to list of practitioners eligible to prescribe buprenorphine until October 1, 2023. The ASAM Treatment of Opioid Use Disorder Course is available for qualifying clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives.

    Qualify
    To qualify for a waiver, NPs, PAs, CRNAs, CNMs, and CNSs must:

    • Be licensed under state law to prescribe Schedule III, IV, or V medications for pain
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat Opioid Use Disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver. 

    1. Providers who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.
    2. Clinicians and healthcare team members working with providers who prescribe buprenorphine in office-based treatment of opioid use disorders.

    ASAM would like to acknowledge the following supporters:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI026793-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

  • Part I: The ASAM Treatment of Opioid Use Disorder Course 8-Hour Online

    Contains 7 Component(s)

    This course covers all approved medications to treat opioid use disorder and provides the 8 hours of education needed to receive a waiver to prescribe buprenorphine in an office-based setting.

    Welcome to The ASAM Treatment of Opioid Use Disorder Course. This course provides 8 hours of education needed to receive a waiver to prescribe buprenorphine in an office-based setting. More information on waiver requirements can be found on the SAMHSA website. This course was updated in August 2018.

    To begin the online course, please log-in to your left and locate the box that says, "Module 1" in the "Contents" tab. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

    Instructions for completing the course can be found in the "Course Instructions" tab. After completing the online modules, corresponding quizzes, and applicable evaluations, return here to claim CME for the course. 

    If you have any questions, please contact education@ASAM.org.

    Learning Objectives:

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorder
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorder
    6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorder
    8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone
    9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorder
    10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorder
    11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder
    12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    For 24-Hour Treatment of Opioid Use Disorder Course issuing AANP CE Credit: Click Here


    This training is divided into two parts of 8 hours and 16 hours. If you have already completed the 8-hour DATA2000 course, you will only need to complete the second part of the 16-hour course.

    Legislation
    Comprehensive Addiction and Recovery Act (CARA)
    ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

    HR6 - SUPPORT for Patients and Communities Act
    HR6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, added qualifying clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives to list of practitioners eligible to prescribe buprenorphine until October 1, 2023. The ASAM Treatment of Opioid Use Disorder Course is available for qualifying clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives.

    Qualify
    To qualify for a waiver, NPs, PAs, CRNAs, CNMs, and CNSs must:

    • Be licensed under state law to prescribe Schedule III, IV, or V medications for pain
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat Opioid Use Disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver. 

    1. Providers who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.
    2. Clinicians and healthcare team members working with providers who prescribe buprenorphine in office-based treatment of opioid use disorders.

    ASAM would like to acknowledge the following supporters:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI026793-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

  • 24-Hour Waiver Training: AAPA

    Contains 2 Product(s)

    Free 24-hour CME education for physician assistants seeking to qualify for a waiver to prescribe buprenorphine in an office-based treatment setting.

    image

    This package contains 24 hours of required education for NP/PA/CRNA/CNM/CNS to qualify for a waiver to prescribe buprenorphine in an office-based setting. This curriculum covers all medications and treatments for opioid use disorder, in addition to other topics including medical maintenance and withdrawal, FDA-approved medications, initial and periodic patient assessment, and counseling and recovery support.

    The collaborative of ASAM, AAPA and AANP identified and reviewed this content to provide the NP/PA training required by CARA.

    The NP/PA 24-Hour Waiver Training is available for free in part by an unrestricted educational grant from Indivior.

    The 16-hour product developed includes all additional education required by the Comprehensive Addiction and Recovery Act (CARA) for physician assistants to successfully apply for a waiver to prescribe buprenorphine for office-based treatment of opioid use disorders.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - New Cumberland, PA - Friday, October 11, 2019

    Product not yet rated Contains 6 Component(s), Includes Credits

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Host: PA Department of Health

    Friday, October 11, 2019 | 8:00 am - 12:30 pm

    Clarion New Cumberland
    148 Sheraton Drive
    New Cumberland, PA 17070

    Overview 

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
    This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. You must complete both portions to receive credit for the course. 

    Getting Started 

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions.If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    1. Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
    2. Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: December 2019

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAPA Credit Designation Statement

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHNone

    Edwin Salsitz, MD, DFASAM

    None

    R. Corey Waller, MD, MS, DFASAM

    None


    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMNone
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone


    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone


    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer


    Johnson & Johnson

    Pfizer Canada
    Grant funding

    Consulting Fees

    Consulting Fees
    Principal
    Investigator


    Consulting


    Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Wilkes-Barre, PA - Friday, October 18, 2019

    Product not yet rated Contains 6 Component(s), Includes Credits

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Host: PA Department of Health

    Friday, October 18, 2019 | 8:00 am - 12:30 pm

    Quality Inn & Suites
    880 Kidder St
    Wilkes-Barre, PA 18702

    Overview 

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
    This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. You must complete both portions to receive credit for the course. 

    Getting Started 

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions.If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    1. Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
    2. Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.

    Accreditation & Disclosures

    Date of Release: July 2015
    Approved Through: December 2019

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AAPA Credit Designation Statement

    This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    Disclosures

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHNone

    Edwin Salsitz, MD, DFASAM

    None

    R. Corey Waller, MD, MS, DFASAM

    None


    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMNone
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone


    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone


    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer


    Johnson & Johnson

    Pfizer Canada
    Grant funding

    Consulting Fees

    Consulting Fees
    Principal
    Investigator


    Consulting


    Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.